Journal of Medicinal and Organic Chemistry

Perspective

Green Biocatalysts: Sustainable Solutions for Modern Chemical Synthesis

Isabella Ricci*

Dept. of Biocatalysis, Roma Classic Univ, Italy

*Author for correspondence:
iricci@rcu.it

Received: 01-Oct-2025, Manuscript No. jmoc-26-184933; **Editor assigned:** 03-Oct-2025, PreQC No. jmoc-26-184933 (PQ); **Reviewed:** 18-Oct-2025, QC No. jmoc-26-184933; **Revised:** 21-Oct-2025, Manuscript No. jmoc-26-184933 (R); **Published:** 31-Oct-2025, DOI: 10.37532/jmoc.2025.8(5).320-321

Introduction

Green biocatalysts represent a cornerstone of sustainable chemistry, offering environmentally friendly alternatives to traditional chemical catalysts. These catalysts, typically enzymes derived from microorganisms, plants, or recombinant sources, facilitate chemical transformations under mild, aqueous, and energy-efficient conditions. By combining high specificity, selectivity, and biodegradability, green biocatalysts enable efficient production of pharmaceuticals, fine chemicals, and biofuels while minimizing hazardous waste, energy consumption, and environmental impact [1-5].

Discussion

The unique advantage of green biocatalysts lies in their ability to catalyze reactions with remarkable regio-, chemo-, and stereoselectivity. Enzymes such as oxidoreductases, hydrolases, and transferases can carry out complex transformations that are difficult or inefficient with conventional chemical methods. For example, lipases are widely employed for esterification and transesterification reactions, while ketoreductases facilitate asymmetric reduction of ketones, producing enantiomerically pure intermediates for drug synthesis.

Advances in enzyme engineering and directed evolution have expanded the capabilities of green biocatalysts. Tailoring enzyme structure enhances stability under industrial conditions, broadens substrate scope, and improves catalytic efficiency. Immobilization techniques further improve reusability and operational stability, allowing biocatalysts to function in continuous flow reactors or non-aqueous media. These innovations enable scalable and economically viable processes while reducing reliance on toxic reagents, extreme temperatures, and organic solvents.

Applications of green biocatalysts span pharmaceuticals, agrochemicals, food industries, and renewable energy. In drug synthesis, enzymes facilitate stereoselective transformations, minimizing the need for protective groups and hazardous reagents. Biocatalytic processes in biofuel production and biomass conversion enhance sustainability by using renewable feedstocks and reducing greenhouse gas emissions. Additionally, the integration of biocatalysis with green chemistry principles supports circular economy strategies, emphasizing waste reduction, energy efficiency, and environmentally benign processes.

Challenges in the adoption of green biocatalysts include cost, enzyme stability, and substrate limitations. However, advances in protein engineering, computational modeling, and fermentation technology are rapidly addressing these barriers, making biocatalysis more accessible for industrial applications.

Conclusion

Green biocatalysts offer a sustainable, efficient, and versatile approach to chemical synthesis, combining high selectivity with environmental responsibility. By enabling mild, energy-efficient, and waste-minimized processes, they are transforming pharmaceutical manufacturing, chemical production, and renewable energy industries. Continued innovations in enzyme engineering, immobilization, and process design will further enhance their industrial applicability, solidifying green biocatalysts as essential tools for sustainable and next-generation chemical synthesis.

References

1. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, et al. (2019) Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med 14; 380:1022-1032.
2. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, et al. (2005) Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44: 467-94.
3. Phan BA, Dayspring TD, Toth PP (2012) Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 8:415-27.
4. Parthiban C (2022) RP-HPLC Method Development and Validation for the Simultaneous Estimation of Bempedoic Acid and Ezetimibe in Pharmaceutical Dosage Form. IJPPR: December 26: 1.
5. Jain (2022) Development and Validation of Novel RP-HPLC Method for the Simultaneous Estimation of Ezetimibe and Bempedoic Acid in a Tablet dosage Form. IJPSR 13: 4680-4685.